Kac, Przemysław R.
Gonzalez-Ortiz, Fernando
Simrén, Joel
Dewit, Nele
Vanmechelen, Eugeen
Zetterberg, Henrik
Blennow, Kaj
Ashton, Nicholas J.
Karikari, Thomas K.
Funding for this research was provided by:
University of Gothenburg
Article History
Received: 9 February 2022
Accepted: 27 April 2022
First Online: 11 May 2022
Declarations
:
: This study, using leftover samples from patients seen at the Sahlgrenska University Hospital, was approved by the ethics committee at the University of Gothenburg (#EPN 140811).
: Not applicable
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Pinteon Therapeutics, Red Abbey Labs, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave and has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche. KB has served as a consultant or at advisory boards for Axon, Biogen, CogRx, Lilly, MagQu, Novartis, and Roche Diagnostics. HZ and KB are co-founders of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. EVM is a co-founder of ADx NeuroSciences. ND is an employee of ADx NeuroSciences. The other authors declare no competing interest.